Anti-HIV TECHNOLOGY AND PRODUCTS

     Using its proprietary technology, BioClonetics has created a proprietary cell line that produces a fully human monoclonal antibody (known as Clone 3) that specifically targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). This capability to neutralize the virus means that Clone 3 may be used successfully to treat those infected with HIV and provide an ideal immunogen in the development of an active anti-HIV/AIDS vaccine that is both prophylactic and therapeutic.
     Additional supplemental products may be produced as wel, for example vaginal creams for prevention of transmission of the virus.  Clone 3 has the potential to enormously reduce the incidence of mother to child transmission (MTCT) of the virus.  Not only might it prevent in-utero  viral transmission but, postnatally, effective treatment can be administered without fear of antiretroviral (ARV) toxicity or resistance.
 
    Each of these distinct products flow from the BioClonetics technology.  The first is the use of the antibody itself or a recombinant of the antibody.  The second is the Clone 3 vaccine, the third is a mini-antibody or paratope of the Clone 3 antibody and the fourth is a competitive binding entry-fusion inhibitor that prevent infectivity.
 
     In addition to the Clone 3 monoclonal antibody against HIV, the company has also created human monoclonal antibodies against other infectious diseases, including rabies, influenza A, influenza B, tetanus and diphtheria. This immunotherapeutic technology platform can be readily applied to creating monoclonal antibodies against other pathogenic diseases including HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto=immune disease and the Ebolavirus.  BioClonetics' antibody-based immunotherapeutics platform can be utilized across both human and animal infectious-disease applications. For example, the technology can be used to produce treatment for elephant and equine diseases that threaten these species.

Several products will be produced from this technology including:

(A) Use of the Clone 3 antibody to treat HIV.

(B) A Clone 3 vaccine using the Clone 3 epitope on gp41 as an immunogen vaccine.

(C) Use of a small molecule mini-antibody (which is less expensive to produce) for treating those with the virus.

(D) Production of a competitive binding entry-fusion inhibitor to also treat those with the virus.

As the following illustration depicts, these several products flow from the Company’s technology, as depicted in this illustration: